Frequentist Approach for Detecting Heterogeneity in Meta-Analysis Pair-Wise Comparisons: Enhanced Q-Test Use By Using I2 and H2 Statistics

Laliman, V.; Roiz, Javier

doi:10.1016/j.jval.2014.08.1942

Cited by 9 publications

(9 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The percent of total variance due to study heterogeneity was estimated using the I squared (I 2 ) statistic. Heterogeneity across treatment types was assessed using the between-group Q statistic [ 27 ]. Publication bias was evaluated using Egger’s test [ 28 ].…”

Section: Methodsmentioning

confidence: 99%

Systematic review and meta-analysis of selected toxicities of approved ALK inhibitors in metastatic non-small cell lung cancer

Costa

Talamantes

et al. 2018

Oncotarget

View full text Add to dashboard Cite

IntroductionAnaplastic lymphoma kinase (ALK) inhibitors are the mainstay treatment for patients with non-small cell lung carcinoma (NSCLC) harboring a rearrangement of the ALK gene or the ROS1 oncogenes. With the recent publication of pivotal trials leading to the approval of these compounds in different indications, their toxicity profile warrants an update.Materials and MethodsA systematic literature search was performed in July 2017. Studies evaluating US FDA approved doses of one of the following ALK inhibitors: Crizotinib, Ceritinib, Alectinib or Brigatinib as monotherapy were included. Data were analyzed using random effects meta-analysis for absolute risks (AR), study heterogeneity, publication bias and differences among treatments.ResultsFifteen trials with a total of 2,005 patients with evaluable toxicity data were included in this report. There was significant heterogeneity amongst different studies. The pooled AR of death and severe adverse events were 0.5% and 34.5%, respectively. Grade 3/4 nausea, vomiting, diarrhea, and constipation were uncommon: 2.6%, 2.5%, 2.7%, 1.2%, respectively.ConclusionsALK inhibitors have an acceptable safety profile with a low risk of treatment-related deaths. Important differences in toxicity profile were detected amongst the different drugs.

show abstract

Section: Methodsmentioning

confidence: 99%

Systematic review and meta-analysis of selected toxicities of approved ALK inhibitors in metastatic non-small cell lung cancer

Costa

Talamantes

et al. 2018

Oncotarget

View full text Add to dashboard Cite

show abstract

“…Heterogeneity among studies was assessed through Q statistic and I 2 statistic [ 30 ], where Q approximately obeys a χ 2 distribution with k − 1 degrees of freedom, while k is the number of studies. Specially, P value can be employed to test the significance level of heterogeneity; I 2 = [ Q − (k − 1)]/ Q 100%, varying from 0 to 100%.…”

Section: Methodsmentioning

confidence: 99%

Association of the independent polymorphisms in CDKN2A with susceptibility of acute lymphoblastic leukemia

et al. 2018

View full text Add to dashboard Cite

Acute lymphoblastic leukemia (ALL) is the most common cancer in children, and alterations in CDKN2A were considered to play an important role on leukemogenesis. Two single nucleotide polymorphisms (SNPs) at CDKN2A locus were identified to impact on ALL susceptibility via genome wide association studies, and followed by multiple subsequent replication studies at the specific hits. Here, we conducted a systematic review and meta-analysis to re-evaluate the association of both SNPs (rs3731217 and rs3731249) with ALL susceptibility by gathering the data from 24 independent studies, totally containing 7922 cases/21503 controls for rs3731217 and 6295 cases/24191 controls for rs3731249. Both SNPs were significantly associated with ALL risk (odds ratio [OR] = 0.72 and 2.26 respectively), however, exhibit race-specific pattern. In summary, our meta-analysis indicated that two SNPs at CDKN2A locus are associated with ALL susceptibility independently mainly in Caucasians. Future large-scale studies are required to validate the associations in other ethnicities.

show abstract

“…HR and 95% CI were recorded to assess the strong connection between different PLR levels and CRC prognosis. The heterogeneity of included studies was analyzed and evaluated by combining the Cochrane Q test and I 2 test ( 36 ). A P -value <0.1 for Q statistic test or I 2 > 50% was considered to be significantly heterogeneous.…”

Section: Methodsmentioning

confidence: 99%

Potential impact of platelet-to-lymphocyte ratio on prognosis in patients with colorectal cancer: A systematic review and meta-analysis

Guo

Gao

et al. 2023

Front. Surg.

View full text Add to dashboard Cite

BackgroundNumerous studies have confirmed that inflammation promotes the occurrence, development and prognosis of colorectal cancer (CRC).ObjectiveThis study focuses on the potentially prognostic value of the platelet-to-lymphocyte ratio (PLR) in CRC patients.Data SourcesThis study was registered at PROSPERO (ID: CRD42020219215). Relative studies were searched on PubMed, Cochrane Library, Embase, Web of Science, and clinical trial databases by two back-to-back reviewers. Study Selection and Intervention: Studies were screened according to the predetermined inclusion and exclusion criteria, comparing prognosis differences between low PLR levels and high PLR levels for CRC patients. Main Outcome Measures: Studies were integrated and compared to analyze the value of PLR in predicting overall survival (OS), progression-free survival (PFS), cancer-specific survival (CSS), disease-free survival (DFS) and recurrence-free survival (RFS) of CRC. Results: Outcomes were compared using Review Manager (version 5.4) software from Cochrane Collaboration. A total of 27 literary works, including 13,330 patients, were incorporated into our study. The final results showed that higher PLR levels had worse OS (hazard ratio [HR] = 1.40, 95% confidence interval [CI] = 1.21–1.62, P < 0.00001), DFS (HR = 1.44, 95% CI = 1.09–1.90, P = 0.01) and RFS (HR = 1.48, 95% CI = 1.13–1.94, P = 0.005) than lower PLR levels, respectively. However, there was no evidence of significance for PFS (HR = 1.14, 95% CI = 0.84–1.54, P = 0.40) and CSS (HR = 1.16, 95% CI = 0.88–1.53, P = 0.28) in the final meta-analysis.LimitationsOur study has the following limitations. First of all, we only included literature published in English, which means that some publication bias may be inevitable. In addition, our study used aggregate data, not individual data; furthermore, we did not define the exact cut-off value representing the PLR level.ConclusionAn elevated PLR seems to be an adverse prognostic factor affecting survival outcomes in patients with CRC. Meanwhile, more prospective studies are required to confirm our conclusion.PROSPERO ID: CRD42020219215.

show abstract

Frequentist Approach for Detecting Heterogeneity in Meta-Analysis Pair-Wise Comparisons: Enhanced Q-Test Use By Using I2 and H2 Statistics

Cited by 9 publications

References 0 publications

Systematic review and meta-analysis of selected toxicities of approved ALK inhibitors in metastatic non-small cell lung cancer

Systematic review and meta-analysis of selected toxicities of approved ALK inhibitors in metastatic non-small cell lung cancer

Association of the independent polymorphisms in CDKN2A with susceptibility of acute lymphoblastic leukemia

Potential impact of platelet-to-lymphocyte ratio on prognosis in patients with colorectal cancer: A systematic review and meta-analysis

Contact Info

Product

Resources

About